First phase 3 data set
In mid-2017, Alnylam Pharmaceuticals (ALNY) expects to release top-line data from its Apollo Phase 3 trial. This trial evaluates investigational RNA interference (or RNAi) therapy, patisiran, as a therapy for patients suffering with polyneuropathy due to hereditary TTR-mediated amyloidosis (or hATTR amyloidosis).
If these results are positive, the company expects to submit applications seeking approval for the drug in the US and Europe by end of 2017. To learn more about this phase 3 clinical trial, please read ALNY Completes Enrollment for Patisiran’s Phase 3 Trial in 2016.
These developments are expected to accelerate the transition of Alnylam Pharmaceuticals from being a research and development–focused organization to a commercial organization. It may also have a positive impact ALNY stock, as well as on the SPDR S&P Biotech ETF (XBI). Alnylam Pharmaceuticals (ALNY) makes up ~2.4% of XBI’s total portfolio holdings.
Analyst recommendations for Alnylam Pharmaceuticals
Of the 15 analysts covering Alnylam Pharmaceuticals (ALNY) in February 2017, two rated the company as a “strong buy,” six rated it as a “buy,” and seven rated ALNY as a “hold.” None of the analysts rated the company as a “sell” or a “strong sell.” Approximately 56% of analysts gave the company some form of “buy” recommendation.
Of the 13 analysts covering United Therapeutics (UTHR) in February 2017, ~31% rated the company as a “buy.” Approximately 44% of the 25 analysts covering Vertex Pharmaceuticals (VRTX) gave it “buy” recommendations in February 2017. Further, ~81% of the 21 analysts covering Alexion Pharmaceuticals (ALXN) rated the company as a “buy” this month.
In the next article, we’ll discuss Alnylam Pharmaceuticals’s research programs for its investigational therapy, Patisiran, in greater detail.